期刊文献+

ShRNA表达载体干涉Cyclin D1分子抑制骨肉瘤细胞系SOSP-9607的增殖 被引量:3

ShRNA of Cyclin D1 decreased the proliferation of human osteosarcoma cell line SOSP-9607
下载PDF
导出
摘要 目的:探讨Cyclin D1 shRNA(short hairpin RNA)对骨肉瘤细胞系SOSP-9607增殖和凋亡的影响。方法:利用Cy-clin D1 shRNA表达载体,稳定转染骨肉瘤细胞系SOSP-9607,分别采用RT-PCR和Western blot分别从mRNA水平和蛋白水平上检测CyclinD1的变化;流式细胞术检测骨肉瘤细胞Cyc-linD1周期和凋亡率的变化;CCK-8检测干涉Cyclin D1对骨肉瘤细胞增殖的影响。结果:稳定转染Cyclin D1 shRNA载体后骨肉瘤细胞的Cyclin D1 mRNA和蛋白的表达均被明显抑制。与对照组相比,骨肉瘤细胞增殖被显著抑制(P<0.05)。同时,细胞发生G0/1期阻滞,G1/S期比例增加(P<0.01)。结论:Cyclin D1 shRNA载体可下调目的基因的表达,有效的抑制骨肉瘤细胞SOSP-9607的增殖,发生G1/S期阻滞。 AIM: To investigate the effect of Cyclin D1 shRNA on the apoptosis and proliferation of human osteosarcoma cell line SOSP-9607. METHODS: Human Cyclin D1 shRNA vector was stably transfected into SOSP-9607 osteosarcoma cells. The mRNA and protein cxpression levels of Cyclin DI were detected by semiquantitative RT-PCR and Western blot respectively. The cell cycle and pretiferation of osteosarcoma cells were examined by FCM analysis and CCK-8 method, respectively. RESULTS: After stable transfection of Cyclin D1 shRNA, the expression of Cyclin DI were inhibited at mRNA and protein levels. The proliferation of SOSP-9607 osteosarcoma cells was inhibited. The difference was significant compared with control groups (P 〈 0.05). At the same time, Cyclin D1 shRNA transfection increased G0/1 phage content and decreased S phage content. CONCLUSION: Cyclin D1 shRNA could down-regulate the expression of Cyclin D1, effectively inhibit the proliferation of osteosarcoma cells, and have significant effect on the cell cycle.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2009年第12期1155-1157,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 陕西省科技攻关课题[2006K09-G2(8)]
关键词 骨肉瘤 CYCLIN D1 SHRNA 周期 增殖 osteosarcoma Cyclin D1 shRNA cell cycle proliferation
  • 相关文献

参考文献8

二级参考文献34

共引文献16

同被引文献23

  • 1刘叶,丁佳逸,沈炜亮,赵兴,范顺武.小干扰RNA抑制MG-63细胞cyclin A2基因的表达[J].中华肿瘤杂志,2007,29(9):670-675. 被引量:1
  • 2Tsao AK, Roberson JR, Christie MJ, et al.Biomechanical and clinical evaluations of a porous tantalum implant for the treatment of early-stage osteonecrosis[J].J Bone Joint Surg Am, 2005,87 ( Suppl 2 ) : 22-27.
  • 3Balla VK, Bodhak S, bose S, et al. Porous tantalum structures for bone implants: Fabrication mechanical and in vitro biological properties [J].Acta Biomaterialia,2010,6 (8): 3349-3359.
  • 4Tanzer M, Bobyn JD, Krygier J J, et al. Histopatho logic retrieval analys is of clinically failed porous tantalum osteonecrosis implant[J]. J Bone Joint Surg Am,2008,90 ( 6 ): 1282-1289.
  • 5Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting [J]. Clin Ortho p Relat Res, 2002 ( 405 ) : 14-23.
  • 6Weiss KR.Cooper GM, Jadlowiec JA, et aI.VEGF and BMP expression in mouse osteosareoma cells[J]. Clin Orthop Relat Res, 2006,450: 111 - 117.
  • 7Hernigou P, Beaujean F. Treatment of osteo necrosis with autologous bone marrow grafting[J]. Clin Orthop Relat Res, 2002(405): 14-23.
  • 8Weiss KR, Cooper GM, Jadlowiec JA, et al. VEGF and BMP expression in mouse osteosarcoma cells[J]. Clin Orthop Relat Res, 2006, 450:111-117.
  • 9Hemigou P, Poignard A, Manicom O, et al. The use of percutaneous autologous bone marrow transplantation in nonunion and avascular nexrosis of bone[J]. J Bone Joint Surg (Br), 2005, 87(7): 896-902.
  • 10孙伟,李子荣,王佰亮,史振才,石少辉.髓芯减压加自体骨髓干细胞移植治疗股骨头坏死的早期随访结果[J].中国组织工程研究与临床康复,2008,12(12):2231-2234. 被引量:24

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部